Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd....
Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks Treatment High Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary Medications With Patient’s Pruritus Almost...
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton Syndrome Until...
Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and Angiofibromas Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration Company Plans to Submit Investigational New Drug Applications and Initiate...
Groundbreaking data from first whole body application of QRX003 underscores potential efficacy Transformational improvement in disease state after just 2 weeks of treatment Clear visual evidence of skin healing observed Improvement has eliminated need for previously...
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints Observed Data Supports QRX003 Mechanism of Action as a Competitive Broad Spectrum Serine Protease Inhibitor ASHBURN, Va., Jan....
